000305670 001__ 305670
000305670 005__ 20251110115720.0
000305670 0247_ $$2doi$$a10.1158/1055-9965.EPI-25-1084
000305670 0247_ $$2pmid$$apmid:41196234
000305670 0247_ $$2ISSN$$a1055-9965
000305670 0247_ $$2ISSN$$a1538-7755
000305670 037__ $$aDKFZ-2025-02300
000305670 041__ $$aEnglish
000305670 082__ $$a610
000305670 1001_ $$00000-0002-8107-3011$$aMichaud, Dominique S$$b0
000305670 245__ $$aAntibody responses to 11 Fusobacterium proteins and colorectal cancer-specific and overall survival in the EPIC cohort.
000305670 260__ $$aPhiladelphia, Pa.$$bAACR$$c2025
000305670 3367_ $$2DRIVER$$aarticle
000305670 3367_ $$2DataCite$$aOutput Types/Journal article
000305670 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762762924_2549711
000305670 3367_ $$2BibTeX$$aARTICLE
000305670 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305670 3367_ $$00$$2EndNote$$aJournal Article
000305670 500__ $$aepub
000305670 520__ $$aWhile there is evidence that Fusobacterium spp. in colon tissue is associated with prognosis, less is known about the association between antibody response to antigens expressed by fusobacteria and colorectal cancer (CRC)-specific mortality.Antibody responses to 11 Fusobacterium nucleatum (ATCC 25586) antigens were measured in pre-diagnostic blood for 471 incident CRC cases (median time to diagnosis=3.4 years), among whom 188 CRC-specific deaths and 250 total deaths were confirmed over a median follow-up of 9.2 years in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Cox models were conducted to examine associations between antigen seropositivity and CRC-specific mortality.Seropositivity to fusobacterial antigens was not associated with overall or CRC-specific mortality, individually or combined. Similar results were observed when restricting to patients who donated blood <3 years prior to cancer diagnosis. When restricting to individuals diagnosed at an earlier age of onset (<55 years; N=74), we observed positive associations for seropositivity to three fusobacteria antigens reflecting different putative autotransporter adhesins. The strongest association was for Fn1893 antigen seropositivity (HR: 6.95, 95% CI: 1.78-27.2, compared to none) and CRC-specific mortality, but confidence intervals were wide.While null overall, this is the first study to observe an association between antibody response to fusobacteria and CRC-specific mortality among individuals with earlier onset CRC. Future studies are needed to confirm these findings and understand the role of systemic antibody responses to fusobacteria in cancer.Specific antigens expressed by fusobacteria may play a role in mortality from earlier onset CRCs.
000305670 536__ $$0G:(DE-HGF)POF4-319H$$a319H - Addenda (POF4-319H)$$cPOF4-319H$$fPOF IV$$x0
000305670 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305670 7001_ $$00000-0003-3676-8954$$aPlatz, Elizabeth A$$b1
000305670 7001_ $$00000-0002-5092-0150$$aGarrett, Wendy S$$b2
000305670 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b3$$udkfz
000305670 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b4$$udkfz
000305670 7001_ $$00000-0003-4224-7821$$aPasanisi, Fabrizio$$b5
000305670 7001_ $$00000-0001-9530-9374$$aAbilleira, Eunate$$b6
000305670 7001_ $$00000-0001-5438-970X$$aPala, Valeria$$b7
000305670 7001_ $$00000-0002-2185-2179$$aMilani, Lorenzo$$b8
000305670 7001_ $$00000-0002-6396-7265$$aCastilla, Jesús$$b9
000305670 7001_ $$00000-0001-9491-2956$$aRodriguez Palacios, Daniel$$b10
000305670 7001_ $$00000-0003-2666-414X$$aTumino, Rosario$$b11
000305670 7001_ $$00000-0002-5758-9069$$aMasala, Giovanna$$b12
000305670 7001_ $$00000-0001-9776-3773$$aFarràs, Marta$$b13
000305670 7001_ $$00000-0003-4817-0757$$aSánchez, Maria-Jose$$b14
000305670 7001_ $$00000-0002-4102-6835$$aPapier, Keren$$b15
000305670 7001_ $$00000-0001-7157-419X$$aSeveri, Gianluca$$b16
000305670 7001_ $$00000-0002-8452-8472$$aTsilidis, Konstantinos K$$b17
000305670 7001_ $$00000-0002-0573-1852$$aJenab, Mazda$$b18
000305670 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia Anna$$b19$$udkfz
000305670 7001_ $$00000-0003-1668-8770$$aHughes, David J$$b20
000305670 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-25-1084$$pnn$$tCancer epidemiology, biomarkers & prevention$$vnn$$x1055-9965$$y2025
000305670 909CO $$ooai:inrepo02.dkfz.de:305670$$pVDB
000305670 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000305670 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000305670 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000305670 9131_ $$0G:(DE-HGF)POF4-319H$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000305670 9141_ $$y2025
000305670 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2022$$d2024-12-10
000305670 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-10
000305670 9201_ $$0I:(DE-He78)D320-20160331$$kD320$$lInfektionen und Krebs-Epidemiologie$$x0
000305670 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x1
000305670 980__ $$ajournal
000305670 980__ $$aVDB
000305670 980__ $$aI:(DE-He78)D320-20160331
000305670 980__ $$aI:(DE-He78)C020-20160331
000305670 980__ $$aUNRESTRICTED